Aspartate ammonium ion lyase mutants and uses thereof
By mutating the 69th amino acid of aspartate ammonium ion lyase in Escherichia coli, the catalytic activity of the enzyme was improved, solving the problem of enzyme activity downregulation in the prior art and realizing the enhancement of lysine synthesis capacity.
Patent Information
- Application Number
- CN202210141287.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-02-16
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2042-02-16
AI Technical Summary
In the prior art, mutations in aspartate ammonium ion lyase lead to loss or downregulation of enzyme activity, and no mutants with enhanced enzyme activity have been reported, thus affecting lysine synthesis efficiency.
The catalytic activity of the aspartate ammonium ion lyase in Escherichia coli was improved by mutating the 69th amino acid to aspartic acid or leucine, and the synthesis of aspartic acid was enhanced by expressing the mutant in Escherichia coli through recombinant technology.
It significantly improved the synthesis of aspartic acid and the production capacity of downstream metabolites, and increased the yield and conversion rate of lysine.
Smart Images

Figure BDA0003507071050000111 
Figure BDA0003507071050000121
Abstract
Description
Technical Field
[0001] This invention relates to the field of microbial technology, specifically to aspartate ammonium ion lyase mutants and their applications. Background Technology
[0002] Escherichia coli is a Gram-negative bacterium with advantages such as rapid growth, a clear genetic background, and well-established metabolic engineering techniques. Therefore, E. coli is widely used in industrial fermentation to produce L-amino acids, nucleotides, and other organic acids.
[0003] Lysine is the world's second most produced amino acid, widely used in animal feed, pharmaceuticals, and the food industry. Approximately 90% of lysine is used in the feed industry, and 10% in the food and pharmaceutical sectors. When used as an animal feed additive, lysine helps the body absorb other amino acids, thereby improving feed quality.
[0004] Lysine synthesis in *E. coli* begins with aspartic acid and proceeds through multiple enzymatic reactions to obtain lysine. Aspartic acid serves as a direct precursor in lysine synthesis, and fortification of its supply can effectively improve lysine yield. A key enzyme catalyzing aspartic acid production in *E. coli* is aspartate ammonium ion lyase, encoded by the aspA gene. This enzyme can amination fumarate, an intermediate product of the TCA cycle, to aspartic acid in a single step. Currently, there are reports of increasing the expression level of aspartate ammonium ion lyase by introducing multiple copies of the gene or enhancing expression through promoter enhancement. Some literature also reports that mutations in specific amino acids at certain positions of this enzyme can lead to loss or downregulation of enzyme activity. However, there are no reports of obtaining aspartate ammonium ion lyase mutants with enhanced enzyme activity through mutation. Summary of the Invention
[0005] The purpose of this invention is to provide an aspartate ammonium ion lyase mutant and its applications. Another purpose of this invention is to provide recombinant microorganisms expressing this aspartate ammonium ion lyase mutant and their applications.
[0006] Specifically, the present invention provides the following technical solutions:
[0007] The present invention provides an aspartate ammonium ion lyase mutant having an amino acid sequence as shown in SEQ ID NO.1 or 2.
[0008] The aspartate ammonium ion lyase mutants with sequences as shown in SEQ ID NO.1 and SEQ ID NO.2 were obtained by mutating the 69th amino acid of wild-type aspartate ammonium ion lyase in Escherichia coli to aspartic acid and leucine, respectively.
[0009] This invention discovers that mutating the 69th amino acid of aspartate ammonium ion lyase to aspartic acid and leucine can significantly improve the catalytic activity of aspartate ammonium ion lyase. The increased activity of aspartate ammonium ion lyase can enhance the synthesis of aspartic acid, which in turn is beneficial to improving the synthesis of aspartic acid and metabolites with aspartic acid as a precursor. Among these, mutating the 69th amino acid to aspartic acid has a significantly better effect.
[0010] Those skilled in the art should understand that adding a tagged protein to the N-terminus or C-terminus of the above-mentioned aspartate ammonium ion lyase mutant sequence or fusing it with other proteins to form a fusion protein will not significantly change the activity of the above-mentioned aspartate ammonium ion lyase without altering its structure. Therefore, the tagged protein or fusion protein is also within the scope of protection of this invention.
[0011] The present invention also provides a nucleic acid molecule encoding the aspartate ammonium ion lyase mutant described above.
[0012] Based on the amino acid sequence of the aspartate ammonium ion lyase mutant, those skilled in the art can determine the nucleotide sequence of the nucleic acid molecule encoding the mutant. Due to codon degeneracy, there is more than one possible sequence for the aforementioned nucleic acid molecule, and all nucleic acid molecules capable of encoding the aforementioned aspartate ammonium ion lyase mutant are within the scope of protection of this invention.
[0013] The present invention also provides biological materials containing the nucleic acid molecules, wherein the biological materials are expression cassettes, vectors or host cells.
[0014] The expression cassette may be a recombinant DNA molecule obtained by linking elements upstream or downstream of the gene to drive its transcription and translation.
[0015] The vector may be an expression vector or a cloning vector, including but not limited to plasmid vectors, bacteriophage vectors, viral vectors, transposons, etc.
[0016] The host cell may be a microbial cell.
[0017] Based on the above-mentioned aspartate ammonium ion lyase mutant, the present invention provides a recombinant microorganism expressing the above-mentioned aspartate ammonium ion lyase mutant.
[0018] The above-described mutant expressing aspartate ammonium ion lyase can be achieved using any one or more of the following methods:
[0019] (1) Replace (mutate) the original aspartate ammonium ion lyase mutant coding gene on the chromosome of the starting strain with the coding gene of the aspartate ammonium ion lyase mutant.
[0020] (2) Introduce a vector, such as a plasmid, containing the encoding gene of the aspartate ammonium ion lyase mutant into the starting strain;
[0021] (3) Add at least one copy of the aspartate ammonium ion lyase mutant gene to the chromosome of the starting strain.
[0022] Preferably, the recombinant microorganism expresses the aspartate ammonium ion lyase mutant described above, but does not express the original aspartate ammonium ion lyase in its originating strain.
[0023] More preferably, in the recombinant microorganism, the gene encoding aspartate ammonium ion lyase is replaced with the nucleic acid molecule encoding the aspartate ammonium ion lyase mutant described above.
[0024] The recombinant microorganisms mentioned above are Escherichia coli bacteria, preferably Escherichia coli.
[0025] The starting strain mentioned above refers to the starting strain used to replace the gene encoding aspartate ammonium ion lyase with the gene encoding the aspartate ammonium ion lyase mutant. That is, the recombinant microorganism can be obtained by replacing the gene encoding aspartate ammonium ion lyase in the starting strain with the gene encoding the aspartate ammonium ion lyase mutant.
[0026] The recombinant microorganism obtained by mutating the aspartate ammonium ion lyase encoding gene in the starting strain to the gene encoding the aspartate ammonium ion lyase mutant has significantly improved the yield and conversion rate of aspartic acid or metabolites with aspartic acid as a precursor compared with the starting strain.
[0027] Preferably, the starting strain is an Escherichia coli capable of synthesizing and accumulating lysine.
[0028] In one embodiment of the present invention, the starting strain is lysine-producing Escherichia coli MHZ-0914 obtained by mutagenesis. This strain was deposited on June 1, 2021, at the China General Microbiological Culture Collection Center (CGMCC, address: No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences, 100101, China), with accession number CGMCC No. 22648, and classified as Escherichia coli.
[0029] The present invention also provides a method for constructing the recombinant microorganism described above, the method comprising: replacing the gene encoding aspartate ammonium ion lyase in the starting strain of the recombinant microorganism with the gene encoding the aspartate ammonium ion lyase mutant.
[0030] The above-mentioned gene replacement can be achieved using conventional techniques in the field, such as replacing the gene encoding aspartate ammonium ion lyase on the chromosome of the starting strain with the gene encoding the aspartate ammonium ion lyase mutant using homologous recombination methods (including but not limited to the CRISPR recombination system).
[0031] The present invention further provides any one of the following applications of the aspartate ammonium ion lyase mutant, the nucleic acid molecule, the biological material, or the recombinant microorganism:
[0032] (1) Application in the construction of microorganisms for the production of aspartic acid or metabolites with aspartic acid as a synthetic precursor;
[0033] (2) Application in the fermentation production of aspartic acid or metabolites using aspartic acid as a synthetic precursor;
[0034] (3) Application in increasing the yield and / or conversion rate of aspartic acid or metabolites with aspartic acid as a synthetic precursor in microorganisms.
[0035] Preferably, in the above-described applications, the metabolite derived from aspartic acid as a synthetic precursor is lysine. The microorganism is a bacterium of the genus *Escherichia*, preferably *Escherichia coli*.
[0036] This invention provides a method for fermenting to produce aspartic acid or a metabolite using aspartic acid as a synthetic precursor. The method includes: culturing the recombinant microorganisms described above to obtain a culture, and separating and extracting the culture to obtain aspartic acid or a metabolite using aspartic acid as a synthetic precursor.
[0037] Specifically, the above method includes: inoculating the recombinant microorganism into a seed culture medium for seed culture to obtain a seed liquid; inoculating the seed liquid into a fermentation culture medium for culture to obtain a fermentation broth; and separating and extracting the fermentation broth to obtain aspartic acid or a metabolite with aspartic acid as a synthetic precursor.
[0038] Preferably, the metabolite of aspartic acid as a synthetic precursor is lysine.
[0039] Preferably, the fermentation medium comprises the following components: glucose 45-55 g / L, ammonium sulfate 20-30 g / L, yeast extract 3-5 g / L, potassium dihydrogen phosphate 1-2 g / L, magnesium sulfate heptahydrate 0.8-1.2 g / L, ferrous sulfate 0.02-0.04 g / L, manganese sulfate 0.02-0.04 g / L, calcium carbonate 0-30 g / L, and pH 6.5-7.5.
[0040] The beneficial effects of this invention are as follows: The aspartate ammonium ion lyase mutant provided by this invention significantly enhances the enzyme activity of aspartate ammonium ion lyase. This mutant has significantly higher catalytic efficiency, which can promote the synthesis of aspartic acid, thereby enhancing the synthesis and accumulation of downstream metabolites of aspartic acid. The lysine synthesis capacity of recombinant microorganisms constructed using this aspartate ammonium ion lyase mutant is significantly improved, and the yield and conversion rate of lysine are significantly increased. Detailed Implementation
[0041] The amino acid sequence of the aspartate ammonium ion lyase mutant provided by the present invention is shown in SEQ ID NO.1 or SEQ ID NO.2.
[0042] The present invention also provides recombinant microorganisms expressing the above-mentioned aspartate ammonium ion lyase mutant, wherein the recombinant microorganisms are preferably recombinant Escherichia coli. The recombinant Escherichia coli is obtained by mutating the original aspartate ammonium ion lyase coding gene in the starting strain to the coding gene of the above-mentioned aspartate ammonium ion lyase mutant.
[0043] The present invention also provides a method for producing lysine by fermentation using the above-mentioned recombinant microorganisms, the method comprising: culturing the above-mentioned recombinant microorganisms to obtain a culture, and separating and extracting lysine from the culture.
[0044] The following examples are used to illustrate the present invention, but are not intended to limit the scope of the invention.
[0045] Unless otherwise specified, the techniques or conditions described in the following examples shall be performed in accordance with the techniques or conditions described in the literature in this field, or in accordance with the product instructions. Reagents or instruments whose manufacturers are not specified are all conventional products that can be purchased through legitimate channels.
[0046] The primer names and sequences involved in the following examples are shown in Table 1.
[0047] Table 1 Primer sequence information
[0048] Primer name Sequence (5'-3') pTF-aspA-sgRNA-F tcctaggtataatactagtgttcaggacttcatcacatggttttagagctagaaatagc pTF-aspA-sgRNA-R actagtattatacctaggactgagctagctgtcaag aspA-P69-UF gttcagaccagtaccgattg aspA-P69L-UR acaaagagctgcaaaccattctcaaaagtgtagcgaatgccat aspA-P69L-DF atggcattcgctacacttttgagaatggtttgcagctctttgt aspA-P69-DR acctgaatgggttgcgaatc aspA-P69D-UR acaaagagctgcaaaccattgacaaaagtgtagcgaatgccat aspA-P69D-DF atggcattcgctacacttttgtcaatggtttgcagctctttgt aspA-P69-F1 gtgggcctgaagagagcaag aspA-P69-R1 gtgaatataaccagcacgag
[0049] Example 1: Construction of recombinant bacteria containing the mutant gene aspA (P69D)
[0050] This embodiment uses *Escherichia coli* MHZ-0914 (CGMCC No. 22648) as the starting strain, providing recombinant *E. coli* expressing the aspartate ammonium ion lyase mutant shown in SEQ ID NO. 1 (the 69th amino acid of the aspartate ammonium ion lyase is mutated to aspartic acid). Sequencing analysis revealed the amino acid sequence of the aspartate ammonium ion lyase from *E. coli* MHZ-0914 as shown in SEQ ID NO. 3.
[0051] The method for constructing recombinant Escherichia coli is as follows:
[0052] (1) Construction of pTargetF-N20-aspA(P69D) plasmid and Donor DNA
[0053] Step 1: Using pTF-aspA-sgRNA-F / pTF-aspA-sgRNA-R as primers and plasmid pTargetT as a template, amplify the pTF linear plasmid containing N20. Assemble this linear plasmid at 37°C using the Clone Express Seamless Assembly Kit, then transform it into Trans1-T1 competent cells to obtain pTargetF-N20-aspA(P69D), and perform PCR identification and sequencing verification; this plasmid is used to provide the target sequence.
[0054] Step 2: Using the MG1655 genome as a template, the upstream homologous arm ① was amplified using the aspA-P69-UF / aspA-P69D-UR primer pair. The downstream homologous arm ② was amplified using the aspA-P69D-DF / aspA-P69-DR primer pair. Using ① and ② as templates, the Donor DNA was amplified using the aspA-P69-UF / aspA-P69-DR primer pair.
[0055] (2) Preparation and electroporation of competent cells
[0056] Step 1: Prepare competent cells of CGMCC No.22648 and electroporate the pCas plasmid into these competent cells (the transformation method and the method for preparing competent cells are the same as those in Molecular Cloning III).
[0057] Step 2: Pick a single colony obtained in Step 1 and place it in 5 mL of LB medium containing kanamycin and arabinose to a final concentration of 10 mM. Incubate at 30°C and 200 rpm until OD500. 650 Electrocompetent cells were prepared after 0.4% concentration (the method for preparing competent cells is described in Molecular Cloning III).
[0058] Step 3: Electroporate the pTargetF-N20-aspA(P69D) plasmid and Donor DNA obtained in (1) above into competent cells with pCas (electroplation conditions: 2.5kV, 200Ω, 25μF), spread them on LB plates containing spectinomycin and kanamycin, and incubate at 30°C until single colonies are visible.
[0059] (3) Recombination verification
[0060] Step 1: Use primer pair aspA-P69-F1 / aspA-P69-R1 to perform colony PCR verification on the single colony obtained in step 3 of (2) above;
[0061] Step 2: Amplify the PCR-identified strains using primer pair aspA-P69-F1 / aspA-P69-R1, and send the amplification products for sequencing to verify the integrity of the sequence.
[0062] (4) Plasmid elimination
[0063] Step 1: Select the single colony that has been correctly sequenced in (3) above and inoculate it into 5 mL of LB medium containing kanamycin and IPTG at a final concentration of 0.5 mM. After incubating overnight at 30°C, streak it onto an LB plate containing kanamycin.
[0064] Step 2: Pick a single colony from Step 1 and spot it onto LB agar plates containing kanamycin, spectinomycin, and kanamycin alone. Incubate overnight at 30°C. If the colony cannot grow on LB agar plates containing kanamycin or spectinomycin, but grows on LB agar plates containing kanamycin, it indicates that the pTargetF-N20 plasmid has been lost.
[0065] Step 3: Pick positive colonies that have lost the pTargetF-N20 plasmid, inoculate them into antibiotic-free LB medium, incubate at 42°C for 8 hours, then streak them onto LB plates and incubate overnight at 37°C.
[0066] Step 4: Select a single colony obtained in Step 3 and spot it on an LB agar plate containing kanamycin and an LB agar plate without antibiotic. If it cannot grow on the LB agar plate containing kanamycin but grows on the LB agar plate without antibiotic, it indicates that the pCas plasmid is lost. The resulting strain is named 22648-aspA69D.
[0067] Example 2: Construction of recombinant bacteria containing the mutant gene aspA (P69L)
[0068] In this embodiment, Escherichia coli MHZ-0914 (accession number CGMCC No. 22648) was used as the starting strain to provide recombinant Escherichia coli expressing the aspartate ammonium ion lyase mutant shown in SEQ ID NO. 2 (the 69th amino acid of aspartate ammonium ion lyase was mutated to leucine).
[0069] The method for constructing recombinant Escherichia coli is as follows:
[0070] (1) Construction of pTargetF-N20-aspA(P69L) plasmid and Donor DNA
[0071] Step 1: Using pTF-aspA-sgRNA-F / pTF-aspA-sgRNA-R as primers and plasmid pTargetT as a template (see Multigene Editing in the Escherichiacoli Genome via the CRISPR-Cas9 System, Jiang Y, Chen B, et al. Appl. Environ Microbiol, 2015), a linear plasmid with N20 was amplified. This linear plasmid was assembled at 37°C using the Clone Express Seamless Assembly Kit, and then transformed into Trans1-T1 competent cells to obtain pTargetF-N20-aspA (P69L). PCR identification and sequencing verification were then performed.
[0072] Step 2: Using the MG1655 genome as a template, the upstream homologous arm ① was amplified using the aspA-P69-UF / aspA-P69L-UR primer pair. The downstream homologous arm ② was amplified using the aspA-P69L-DF / aspA-P69-DR primer pair. Using ① and ② as templates, the Donor DNA was amplified using the aspA-P69-UF / aspA-P69-DR primer pair.
[0073] (2) Preparation and electroporation of competent cells
[0074] Step 1: Electrotransfer the pCas plasmid (see Multigene Editing in the Escherichia coli Genome via the CRISPR-Cas9 System, Jiang Y, Chen B, et al. Appl. Environ. Microbiol, 2015) into competent cells of Escherichia coli lysine-producing bacterium CGMCC No. 22648 (the transformation method and competent cell preparation method are both based on Molecular Cloning III).
[0075] Step 2: Pick a single colony obtained in Step 1 and place it in 5 mL of LB medium containing kanamycin and arabinose to a final concentration of 10 mM. Incubate at 30°C and 200 rpm until OD500. 650 Electrocompetent cells were prepared after 0.4% concentration (the method for preparing competent cells is described in Molecular Cloning III).
[0076] Step 3: Electroporate the pTargetF-N20-aspA(P69L) plasmid and Donor DNA obtained in (1) above into competent cells with pCas (electroplation conditions: 2.5kV, 200Ω, 25μF), spread them on LB plates containing spectinomycin and kanamycin, and incubate at 30°C until single colonies are visible.
[0077] (3) Recombination verification
[0078] Step 1: Use primer pair aspA-P69-F1 / aspA-P69-R1 to perform colony PCR verification on the single colonies obtained in step (3) of step 2 above;
[0079] Step 2: Amplify the PCR-identified strains using primer pair aspA-P69-F1 / aspA-P69-R1, and send the amplification products for sequencing to verify the integrity of the sequence.
[0080] (4) Plasmid elimination
[0081] Step 1: Select the single colony obtained in (3) above that has been correctly sequenced and inoculate it into 5 mL of LB medium containing kanamycin and IPTG at a final concentration of 0.5 mM. After incubating overnight at 30°C, streak it onto an LB plate containing kanamycin.
[0082] Step 2: Pick the single colonies obtained in Step 1 and spot them onto LB plates containing kanamycin, spectinomycin and kanamycin alone, and incubate overnight at 30°C. If they cannot grow on LB plates containing kanamycin and spectinomycin, but grow on LB plates containing kanamycin, it indicates that the pTargetF-N20 plasmid has been lost.
[0083] Step 3: Pick positive colonies that have lost the pTargetF-N20 plasmid, inoculate them into antibiotic-free LB medium, incubate at 42°C for 8 hours, then streak them onto LB plates and incubate overnight at 37°C.
[0084] Step 4: Select a single colony obtained in Step 3 and spot it on an LB agar plate containing kanamycin and an LB agar plate without antibiotic. If it cannot grow on the LB agar plate containing kanamycin but grows on the LB agar plate without antibiotic, it indicates that the pCas plasmid is lost. The resulting strain is named 22648-aspA69L.
[0085] Example 3: Detection of Aspartate Ammonium Ion Lyase Activity in Recombinant Bacteria
[0086] Escherichia coli CGMCC No. 22648 and recombinant strains 22648-aspA69D and 22648-aspA69L obtained in Examples 1 and 2 were cultured. Proteins were isolated from the cultures, and the activity of aspartate ammonium ion lyase was detected. The specific methods are as follows:
[0087] Cultures of each strain that had reached the logarithmic growth phase were inoculated into 50 mL of LB seed medium. The initial OD after inoculation was... 600 The absorbance was set at 0.3, and the cells were cultured until the absorbance at 600 nm reached 10. Cells were collected by centrifugation, washed twice with 20 mM Tris HCl (pH 8.0), and resuspended in the same buffer. Cells were sonicated to disrupt the cell structure, and the supernatant was collected by centrifugation. The protein content of the supernatant was quantitatively determined using the Bradford method (Bradford, MM 1976. Anal. Biochem. 72: 248-254). The supernatant was used as a crude protein solution for determining the activity of aspartate ammonium ion lyase.
[0088] The activity of aspartate ammonium ion lyase was determined at 37°C and pH 8.0. The reaction mixture consisted of fumaric acid (50 mM), NH4Cl-NH4OH (200 mM, pH 8.0) buffer, and a certain amount of the crude protein solution prepared above was added to initiate the reaction. The amount of substrate consumed was indirectly calculated by measuring the amount of aspartate generated in the reductive ammoniation reaction. The concentration of aspartate was determined by high-performance liquid chromatography (HPLC). One unit (U) of enzyme activity was defined as the amount of enzyme required to catalyze the reduction of fumaric acid to produce 1 μmol of aspartate per minute.
[0089] Three sets of experiments were conducted in parallel, and the average value was taken as the final result. The results are shown in Table 2. The activity of aspartate ammonium ion lyase in recombinant strains 22648-aspA69D and 22648-aspA69L was 2-3 times that of the starting strain CGMCC No.22468. The activity of aspartate ammonium ion lyase in both strains was significantly higher than that in the starting strain CGMCC No.22468, and the increase in activity of aspartate ammonium ion lyase in recombinant strain 22648-aspA69D was significantly higher than that in 22648-aspA69L.
[0090] Table 2. Assay of the activity of aspartate ammonium ion lyase
[0091]
[0092] Example 4: Performance of recombinant strain in producing lysine
[0093] The recombinant bacteria constructed in Examples 1 and 2 were used in lysine fermentation experiments. The culture medium formulation used in the lysine fermentation process is as follows:
[0094] Activation medium: 10 g / L peptone, 10 g / L NaCl, 5 g / L yeast extract, 18 g / L agar powder, adjust pH to 7.0.
[0095] Seed culture medium: glucose 10 g / L, ammonium sulfate 4 g / L, yeast extract 2.0 g / L, potassium dihydrogen phosphate 3 g / L, magnesium sulfate heptahydrate 0.4 g / L, ferrous sulfate 0.01 g / L, manganese sulfate 0.01 g / L, pH 7.0.
[0096] Fermentation medium: glucose 50 g / L, ammonium sulfate 25 g / L, yeast extract 4.0 g / L, potassium dihydrogen phosphate 1.6 g / L, magnesium sulfate heptahydrate 1.0 g / L, ferrous sulfate 0.03 g / L, manganese sulfate 0.03 g / L, calcium carbonate 25 g / L, pH 7.0.
[0097] The lysine fermentation method is as follows:
[0098] (1) Seed activation: Take the strain to be verified from the cryopreservation tube, streak it on the seed activation medium, and incubate at 37℃ for 12h;
[0099] (2) Seed culture: Pick one loop of activated seeds from the plate and inoculate it into a 500 mL Erlenmeyer flask containing 20 mL of seed culture medium. Culture at 33℃ and 220 r / min for 7 h to obtain seed solution;
[0100] (3) Fermentation culture: 2 mL of seed culture was inoculated into a 500 mL Erlenmeyer flask containing 20 mL of fermentation culture medium and cultured at 33 °C and 220 r / min for 12 h to obtain fermentation broth.
[0101] (4) Centrifuge 2 mL of fermentation broth (12000 rpm, 2 min), collect the supernatant, and use HPLC to detect the L-lysine content in the fermentation broth of recombinant bacteria and control bacteria. The L-lysine content detection results are shown in Table 3 (the data in Table 3 are the average values of the three batches of experiments).
[0102] Table 3 Performance test of recombinant bacteria in producing lysine
[0103]
[0104] The fermentation results above indicate that the L-lysine accumulation of the starting strain CGMCC No.22648 was 18.5 g / L, with a conversion rate of 37%. The recombinant strain 22648-aspA69D showed significantly improved lysine yield and conversion rate compared to both the starting strain and the recombinant strain 22648-aspA69L.
[0105] Although the present invention has been described in detail above with general descriptions and specific embodiments, modifications or improvements can be made to it, which will be obvious to those skilled in the art. Therefore, all such modifications or improvements made without departing from the spirit of the present invention fall within the scope of protection claimed by the present invention. sequence list <110> Langfang Meihua Biotechnology Development Co., Ltd. <120> Aspartate ammonium ion lyase mutant and its application <130> KHP211125943.8 <160> 13 <170> SIPOSequenceListing 1.0 <210> 1 <211> 478 <212> PRT <213> Artificial Sequence <400> 1 Met Ser Asn Asn Ile Arg Ile Glu Glu Asp Leu Leu Gly Thr Arg Glu 1 5 10 15 Val Pro Ala Asp Ala Tyr Tyr Gly Val His Thr Leu Arg Ala Ile Glu 20 25 30 Asn Phe Tyr Ile Ser Asn Asn Lys Ile Ser Asp Ile Pro Glu Phe Val 35 40 45 Arg Gly Met Val Met Val Lys Lys Ala Ala Ala Met Ala Asn Lys Glu 50 55 60 Leu Gln Thr Ile Asp Lys Ser Val Ala Asn Ala Ile Ile Ala Ala Cys 65 70 75 80 Asp Glu Val Leu Asn Asn Gly Lys Cys Met Asp Gln Phe Pro Val Asp 85 90 95 Val Tyr Gln Gly Gly Ala Gly Thr Ser Val Asn Met Asn Thr Asn Glu 100 105 110 Val Leu Ala Asn Ile Gly Leu Glu Leu Met Gly His Gln Lys Gly Glu 115 120 125 Tyr Gln Tyr Leu Asn Pro Asn Asp His Val Asn Lys Cys Gln Ser Thr 130 135 140 Asn Asp Ala Tyr Pro Thr Gly Phe Arg Ile Ala Val Tyr Ser Ser Leu 145 150 155 160 Ile Lys Leu Val Asp Ala Ile Asn Gln Leu Arg Glu Gly Phe Glu Arg 165 170 175 Lys Ala Val Glu Phe Gln Asp Ile Leu Lys Met Gly Arg Thr Gln Leu 180 185 190 Gln Asp Ala Val Pro Met Thr Leu Gly Gln Glu Phe Arg Ala Phe Ser 195 200 205 Ile Leu Leu Lys Glu Glu Val Lys Asn Ile Gln Arg Thr Ala Glu Leu 210 215 220 Leu Leu Glu Val Asn Leu Gly Ala Thr Ala Ile Gly Thr Gly Leu Asn 225 230 235 240 Thr Pro Lys Glu Tyr Ser Pro Leu Ala Val Lys Lys Leu Ala Glu Val 245 250 255 Thr Gly Phe Pro Cys Val Pro Ala Glu Asp Leu Ile Glu Ala Thr Ser 260 265 270 Asp Cys Gly Ala Tyr Val Met Val His Gly Ala Leu Lys Arg Leu Ala 275 280 285 Val Lys Met Ser Lys Ile Cys Asn Asp Leu Arg Leu Leu Ser Ser Gly 290 295 300 Pro Arg Ala Gly Leu Asn Glu Ile Asn Leu Pro Glu Leu Gln Ala Gly 305 310 315 320 Ser Ser Ile Met Pro Ala Lys Val Asn Pro Val Val Pro Glu Val Val 325 330 335 Asn Gln Val Cys Phe Lys Val Ile Gly Asn Asp Thr Thr Val Thr Met 340 345 350 Ala Ala Glu Ala Gly Gln Leu Gln Leu Asn Val Met Glu Pro Val Ile 355 360 365 Gly Gln Ala Met Phe Glu Ser Val His Ile Leu Thr Asn Ala Cys Tyr 370 375 380 Asn Leu Leu Glu Lys Cys Ile Asn Gly Ile Thr Ala Asn Lys Glu Val 385 390 395 400 Cys Glu Gly Tyr Val Tyr Asn Ser Ile Gly Ile Val Thr Tyr Leu Asn 405 410 415 Pro Phe Ile Gly His His Asn Gly Asp Ile Val Gly Lys Ile Cys Ala 420 425 430 Glu Thr Gly Lys Ser Val Arg Glu Val Val Leu Glu Arg Gly Leu Leu 435 440 445 Thr Glu Ala Glu Leu Asp Asp Ile Phe Ser Val Gln Asn Leu Met His 450 455 460 Pro Ala Tyr Lys Ala Lys Arg Tyr Thr Asp Glu Ser Glu Gln 465 470 475 <210> 2 <211> 478 <212> PRT <213> Artificial Sequence <400> 2 Met Ser Asn Asn Ile Arg Ile Glu Glu Asp Leu Leu Gly Thr Arg Glu 1 5 10 15 Val Pro Ala Asp Ala Tyr Tyr Gly Val His Thr Leu Arg Ala Ile Glu 20 25 30 Asn Phe Tyr Ile Ser Asn Asn Lys Ile Ser Asp Ile Pro Glu Phe Val 35 40 45 Arg Gly Met Val Met Val Lys Lys Ala Ala Ala Met Ala Asn Lys Glu 50 55 60 Leu Gln Thr Ile Leu Lys Ser Val Ala Asn Ala Ile Ile Ala Ala Cys 65 70 75 80 Asp Glu Val Leu Asn Asn Gly Lys Cys Met Asp Gln Phe Pro Val Asp 85 90 95 Val Tyr Gln Gly Gly Ala Gly Thr Ser Val Asn Met Asn Thr Asn Glu 100 105 110 Val Leu Ala Asn Ile Gly Leu Glu Leu Met Gly His Gln Lys Gly Glu 115 120 125 Tyr Gln Tyr Leu Asn Pro Asn Asp His Val Asn Lys Cys Gln Ser Thr 130 135 140 Asn Asp Ala Tyr Pro Thr Gly Phe Arg Ile Ala Val Tyr Ser Ser Leu 145 150 155 160 Ile Lys Leu Val Asp Ala Ile Asn Gln Leu Arg Glu Gly Phe Glu Arg 165 170 175 Lys Ala Val Glu Phe Gln Asp Ile Leu Lys Met Gly Arg Thr Gln Leu 180 185 190 Gln Asp Ala Val Pro Met Thr Leu Gly Gln Glu Phe Arg Ala Phe Ser 195 200 205 Ile Leu Leu Lys Glu Glu Val Lys Asn Ile Gln Arg Thr Ala Glu Leu 210 215 220 Leu Leu Glu Val Asn Leu Gly Ala Thr Ala Ile Gly Thr Gly Leu Asn 225 230 235 240 Thr Pro Lys Glu Tyr Ser Pro Leu Ala Val Lys Lys Leu Ala Glu Val 245 250 255 Thr Gly Phe Pro Cys Val Pro Ala Glu Asp Leu Ile Glu Ala Thr Ser 260 265 270 Asp Cys Gly Ala Tyr Val Met Val His Gly Ala Leu Lys Arg Leu Ala 275 280 285 Val Lys Met Ser Lys Ile Cys Asn Asp Leu Arg Leu Leu Ser Ser Gly 290 295 300 Pro Arg Ala Gly Leu Asn Glu Ile Asn Leu Pro Glu Leu Gln Ala Gly 305 310 315 320 Ser Ser Ile Met Pro Ala Lys Val Asn Pro Val Val Pro Glu Val Val 325 330 335 Asn Gln Val Cys Phe Lys Val Ile Gly Asn Asp Thr Thr Val Thr Met 340 345 350 Ala Ala Glu Ala Gly Gln Leu Gln Leu Asn Val Met Glu Pro Val Ile 355 360 365 Gly Gln Ala Met Phe Glu Ser Val His Ile Leu Thr Asn Ala Cys Tyr 370 375 380 Asn Leu Leu Glu Lys Cys Ile Asn Gly Ile Thr Ala Asn Lys Glu Val 385 390 395 400 Cys Glu Gly Tyr Val Tyr Asn Ser Ile Gly Ile Val Thr Tyr Leu Asn 405 410 415 Pro Phe Ile Gly His His Asn Gly Asp Ile Val Gly Lys Ile Cys Ala 420 425 430 Glu Thr Gly Lys Ser Val Arg Glu Val Val Leu Glu Arg Gly Leu Leu 435 440 445 Thr Glu Ala Glu Leu Asp Asp Ile Phe Ser Val Gln Asn Leu Met His 450 455 460 Pro Ala Tyr Lys Ala Lys Arg Tyr Thr Asp Glu Ser Glu Gln 465 470 475 <210> 3 <211> 478 <212> PRT <213> Artificial Sequence <400> 3 Met Ser Asn Asn Ile Arg Ile Glu Glu Asp Leu Leu Gly Thr Arg Glu 1 5 10 15 Val Pro Ala Asp Ala Tyr Tyr Gly Val His Thr Leu Arg Ala Ile Glu 20 25 30 Asn Phe Tyr Ile Ser Asn Asn Lys Ile Ser Asp Ile Pro Glu Phe Val 35 40 45 Arg Gly Met Val Met Val Lys Lys Ala Ala Ala Met Ala Asn Lys Glu 50 55 60 Leu Gln Thr Ile Pro Lys Ser Val Ala Asn Ala Ile Ile Ala Ala Cys 65 70 75 80 Asp Glu Val Leu Asn Asn Gly Lys Cys Met Asp Gln Phe Pro Val Asp 85 90 95 Val Tyr Gln Gly Gly Ala Gly Thr Ser Val Asn Met Asn Thr Asn Glu 100 105 110 Val Leu Ala Asn Ile Gly Leu Glu Leu Met Gly His Gln Lys Gly Glu 115 120 125 Tyr Gln Tyr Leu Asn Pro Asn Asp His Val Asn Lys Cys Gln Ser Thr 130 135 140 Asn Asp Ala Tyr Pro Thr Gly Phe Arg Ile Ala Val Tyr Ser Ser Leu 145 150 155 160 Ile Lys Leu Val Asp Ala Ile Asn Gln Leu Arg Glu Gly Phe Glu Arg 165 170 175 Lys Ala Val Glu Phe Gln Asp Ile Leu Lys Met Gly Arg Thr Gln Leu 180 185 190 Gln Asp Ala Val Pro Met Thr Leu Gly Gln Glu Phe Arg Ala Phe Ser 195 200 205 Ile Leu Leu Lys Glu Glu Val Lys Asn Ile Gln Arg Thr Ala Glu Leu 210 215 220 Leu Leu Glu Val Asn Leu Gly Ala Thr Ala Ile Gly Thr Gly Leu Asn 225 230 235 240 Thr Pro Lys Glu Tyr Ser Pro Leu Ala Val Lys Lys Leu Ala Glu Val 245 250 255 Thr Gly Phe Pro Cys Val Pro Ala Glu Asp Leu Ile Glu Ala Thr Ser 260 265 270 Asp Cys Gly Ala Tyr Val Met Val His Gly Ala Leu Lys Arg Leu Ala 275 280 285 Val Lys Met Ser Lys Ile Cys Asn Asp Leu Arg Leu Leu Ser Ser Gly 290 295 300 Pro Arg Ala Gly Leu Asn Glu Ile Asn Leu Pro Glu Leu Gln Ala Gly 305 310 315 320 Ser Ser Ile Met Pro Ala Lys Val Asn Pro Val Val Pro Glu Val Val 325 330 335 Asn Gln Val Cys Phe Lys Val Ile Gly Asn Asp Thr Thr Val Thr Met 340 345 350 Ala Ala Glu Ala Gly Gln Leu Gln Leu Asn Val Met Glu Pro Val Ile 355 360 365 Gly Gln Ala Met Phe Glu Ser Val His Ile Leu Thr Asn Ala Cys Tyr 370 375 380 Asn Leu Leu Glu Lys Cys Ile Asn Gly Ile Thr Ala Asn Lys Glu Val 385 390 395 400 Cys Glu Gly Tyr Val Tyr Asn Ser Ile Gly Ile Val Thr Tyr Leu Asn 405 410 415 Pro Phe Ile Gly His His Asn Gly Asp Ile Val Gly Lys Ile Cys Ala 420 425 430 Glu Thr Gly Lys Ser Val Arg Glu Val Val Leu Glu Arg Gly Leu Leu 435 440 445 Thr Glu Ala Glu Leu Asp Asp Ile Phe Ser Val Gln Asn Leu Met His 450 455 460 Pro Ala Tyr Lys Ala Lys Arg Tyr Thr Asp Glu Ser Glu Gln 465 470 475 <210> 4 <211> 59 <212> DNA <213> Artificial Sequence <400> 4 tcctaggtat aatactagtg ttcaggactt catcacatgg ttttagagct agaaatagc 59 <210> 5 <211> 36 <212> DNA <213> Artificial Sequence <400> 5 actagtatta tacctaggac tgagctagct gtcaag 36 <210> 6 <211> 20 <212> DNA <213> Artificial Sequence <400> 6 gttcagacca gtaccgattg 20 <210> 7 <211> 43 <212> DNA <213> Artificial Sequence <400> 7 acaaagagct gcaaaccatt ctcaaaagtg tagcgaatgc cat 43 <210> 8 <211> 43 <212> DNA <213> Artificial Sequence <400> 8 atggcattcg ctacactttt gagaatggtt tgcagctctt tgt 43 <210> 9 <211> 20 <212> DNA <213> Artificial Sequence <400> 9 acctgaatgg gttgcgaatc 20 <210> 10 <211> 43 <212> DNA <213> Artificial Sequence <400> 10 acaaagagct gcaaaccatt gacaaaagtg tagcgaatgc cat 43 <210> 11 <211> 43 <212> DNA <213> Artificial Sequence <400> 11 atggcattcg ctacactttt gtcaatggtt tgcagctctt tgt 43 <210> 12 <211> 20 <212> DNA <213> Artificial Sequence <400> 12 gtgggcctga agagagcaag 20 <210> 13 <211> 20 <212> DNA <213> Artificial Sequence <400> 13 gtgaatataa ccagcacgag 20
Claims
1. An aspartate ammonium ion lyase mutant, characterized in that, The amino acid sequence of the aspartate ammonium ion lyase mutant is shown in SEQ ID NO.
1.
2. A nucleic acid molecule, characterized in that, It encodes the aspartate ammonium ion lyase mutant of claim 1.
3. A biomaterial containing the nucleic acid molecule of claim 2, characterized in that, The biomaterial is an expression cassette, vector, or host cell.
4. A recombinant Escherichia coli, characterized in that, The recombinant Escherichia coli expresses the aspartate ammonium ion lyase mutant according to claim 1. The starting strain of the recombinant Escherichia coli is Escherichia coli MHZ-0914, which is deposited at the China General Microbiological Culture Collection Center with accession number CGMCC No. 22648.
5. The recombinant Escherichia coli according to claim 4, characterized in that, In the recombinant Escherichia coli, the gene encoding aspartate ammonium ion lyase is replaced with the nucleic acid molecule described in claim 2.
6. The method for constructing recombinant Escherichia coli according to claim 4 or 5, characterized in that, include: The gene encoding aspartate ammonium ion lyase in the starting strain of the recombinant Escherichia coli is replaced with the gene encoding the aspartate ammonium ion lyase mutant of claim 1.
7. The use of an aspartate ammonium ion lyase mutant or a nucleic acid molecule encoding the aspartate ammonium ion lyase mutant or biological material containing the nucleic acid molecule in constructing Escherichia coli for lysine production or improving the lysine yield and / or conversion rate of Escherichia coli; in, The originating strain of Escherichia coli was Escherichia coli MHZ-0914, which was deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 22648. The amino acid sequence of the aspartate ammonium ion lyase mutant is shown in SEQ ID NO.1 or 2; The biomaterial is an expression cassette, vector, or host cell.
8. Application of recombinant Escherichia coli in the fermentation production of lysine; wherein the recombinant Escherichia coli expresses an aspartate ammonium ion lyase mutant, the amino acid sequence of which is shown in SEQ ID NO.1 or 2; The recombinant Escherichia coli originating strain is Escherichia coli MHZ-0914, which is deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 22648.
9. A method for producing lysine by fermentation, characterized in that, include: Recombinant Escherichia coli was cultured to obtain a culture, and lysine was extracted from the culture. The recombinant Escherichia coli expressed an aspartate ammonium ion lyase mutant, the amino acid sequence of which is shown in SEQ ID NO.1 or 2; The recombinant Escherichia coli originating strain is Escherichia coli MHZ-0914, which is deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 22648.
